HLA Antibody Detection (Scheme 6)
UKAS Schedule of Accreditation, Accredited to ISO/IEC 17043:2010 Provider 8351
HLA antibody detection
PURPOSE OF PROGRAMME:
To assess participants' ability to correctly determine the presence of HLA antibodies using all 'screening' methods the laboratory employs for clinical samples
|HLA Antibodies||Presence or absence of HLA Class I or HLA-Class I and Class II antibodies|
MATERIAL PROVIDED: Serum
DISTRIBUTIONS PER YEAR: 2
SAMPLES PER DISTRIBUTION: 6
FREQUENCY OF DISTRIBUTION: As per Distribution Timetable
PROGRAMME OF ANALYSIS:
Results should be submitted via online data entry. Results are expected to be returned within the specified reporting period (please refer to results deadline for each distribution on the UK NEQAS for H&I website or Participants Manual). The majority of UK NEQAS for H&I schemes are assessed on a consensus basis, therefore samples are distributed with the assigned value not being determined. Where a reference result is used, this testing is performed alongside or after the close of the EQA scheme. For these reasons UK NEQAS for H&I is unable to disclose results early.
Participating laboratories will be assessed on the antibody class or classes they designate at registration. The consensus findings for Class I and Class II antibodies are determined separately. Consensus positivity or negativity of each sample is determined by at least 75% of laboratories agreeing on the presence or absence of Class I or Class II antibody. Samples failing to reach the 75% consensus level will not be assessed. The reports of participants registered for Class I and II assessment must be in agreement with the consensus Class I and Class II findings on a serum to achieve an ‘Acceptable’ classification.
Satisfactory performance is making 80% of reports on all sera in agreement with the consensus Class I or both the consensus Class I and Class II antibody findings in a year.
PERSISTENT POOR PERFORMANCE:
Laboratories not meeting the Satisfactory Performance criteria are deemed to have Unsatisfactory Performance and must complete a root cause, corrective and preventative action form.
Histocompatibility & Immunogenetics
The External Quality Assessment Scheme for Histocompatibility and Immunogenetics was founded in 1975 by Dr Heather Dicks and Dr Colin Entwistle at the National Tissue Typing and Reference Laboratory (NTTRL) based at Southmead Hospital in Bristol. In 1989 the Service became known as the UK National External Quality Assessment Service for Histocompatibility and Immunogenetics with Dr Peter Klouda as the service director and Mr Terry Ray as the service manager. The service relocated to a new host organisation in September 2000. UK NEQAS for Histocompatibility and Immunogenetics is now part of the Welsh Blood Service.